Collegium Pharmaceutical (COLL) PT Lowered to $48 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street rallies as Fed's Waller eases rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Barclays flags an "attractive entry point" in this pharma stock
August 20, 2026 3:00 PM EDTBarclays reiterated an Overweight rating on a pharmaceutical name in a note this week, arguing the roughly 20% share decline since second-quarter results has gone too far.
Collegium Pharma (NASDAQ: COLL) (NASDAQ: COLL) is the stock in question.
"Pain-fueled volatility overdone:... More
